- Home
- INTS vs INKT Comparison
INTS vs INKT Comparison
Compare INTS & INKT Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- INTS
- INKT
- Stock Information
- Founded
- INTS 2012
- INKT 2017
- Country
- INTS United States
- INKT United States
- Employees
- INTS N/A
- INKT N/A
- Industry
- INTS Biotechnology: Pharmaceutical Preparations
- INKT Medicinal Chemicals and Botanical Products
- Sector
- INTS Health Care
- INKT Health Care
- Exchange
- INTS Nasdaq
- INKT Nasdaq
- Market Cap
- INTS 9.4M
- INKT 28.9M
- IPO Year
- INTS 2023
- INKT 2021
- Fundamental
- Price
- INTS $0.30
- INKT $7.04
- Analyst Decision
- INTS Strong Buy
- INKT Strong Buy
- Analyst Count
- INTS 3
- INKT 2
- Target Price
- INTS $8.50
- INKT $37.50
- AVG Volume (30 Days)
- INTS 2.5M
- INKT 14.7K
- Earning Date
- INTS 08-07-2025
- INKT 08-12-2025
- Dividend Yield
- INTS N/A
- INKT N/A
- EPS Growth
- INTS N/A
- INKT N/A
- EPS
- INTS N/A
- INKT N/A
- Revenue
- INTS N/A
- INKT N/A
- Revenue This Year
- INTS N/A
- INKT N/A
- Revenue Next Year
- INTS N/A
- INKT N/A
- P/E Ratio
- INTS N/A
- INKT N/A
- Revenue Growth
- INTS N/A
- INKT N/A
- 52 Week Low
- INTS $0.26
- INKT $4.56
- 52 Week High
- INTS $5.10
- INKT $13.79
- Technical
- Relative Strength Index (RSI)
- INTS 36.77
- INKT 47.56
- Support Level
- INTS $0.29
- INKT $6.91
- Resistance Level
- INTS $0.35
- INKT $7.51
- Average True Range (ATR)
- INTS 0.04
- INKT 0.32
- MACD
- INTS 0.02
- INKT -0.02
- Stochastic Oscillator
- INTS 35.10
- INKT 27.28
About INTS Intensity Therapeutics Inc. Common stock
Intensity Therapeutics Inc is a clinical-stage biotechnology company pioneering a new immune-based approach to treat solid tumor cancers. The company leverages its DfuseRxtechnology platform to create new, proprietary drug formulations that, following direct injection, rapidly disperse throughout a tumor and diffuse therapeutic agents into cancer cells. Intensity's product candidates have the potential to induce an adaptive systemic immune response that not only attacks the injected tumor, but also non-injected tumors. Their pipeline is focused on realizing the full potential of INT230-6 in metastatic and local disease settings to help cancer patients with unmet medical need.
About INKT MiNK Therapeutics Inc.
MiNK Therapeutics Inc is a clinical-stage biopharmaceutical company pioneering the discovery, development, and commercialization of allogeneic invariant natural killer T (iNKT) cell therapies to treat cancer and other immune-mediated diseases. The company is advancing a pipeline of both native and next generation engineered iNKT programs, with a platform designed to facilitate scalable and reproducible manufacturing for off-the-shelf delivery.